✦ LIBER ✦

Factor VIII products and inhibitor development: concepts for revision of European regulatory guidelines

✍ Scribed by B. NEUGEBAUER; C. DRAI; M. HAASE; A. HILGER; B. KELLER-STANISLAWSKI; P. LAITINEN-PARKKONEN; D. MENTZER; C. RASMUSSEN; C. RATIGNIER; R. SEITZ

Book ID: 108772917
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 40 KB
Volume: 14
Category: Article
ISSN: 1351-8216
DOI: 10.1111/j.1365-2516.2007.01604.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Factor VIII products and inhibitor devel

Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers)

✍ P. M. MANNUCCI; A. GRINGERI; F. PEYVANDI; E. SANTAGOSTINO 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Source and purity of factor VIII product

Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A

✍ M. E. MANCUSO; P. M. MANNUCCI; A. ROCINO; I. GARAGIOLA; A. TAGLIAFERRI; E. SANTA 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

Immune regulatory gene polymorphisms as

Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients

✍ P. Pinto; K. Ghosh; S. Shetty 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

Development and validation of an affinit

Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII

✍ Brian D. Kelley; Molly Tannatt; Robert Magnusson; Sigrid Hagelberg; James Booth 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 955 KB

## Abstract An affinity chromatography step was developed for purification of recombinant B‐Domain Deleted Factor VIII (BDDrFVIII) using a peptide ligand selected from a phage display library. The peptide library had variegated residues, contained both within a disulfide bond‐constrained ring and f

Intensive peri-operative use of factor V

Intensive peri-operative use of factor VIII and the Arg593→Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A

✍ C.L. ECKHARDT; L.A. MENKE; C.H. VAN OMMEN; J.H. VAN DER LEE; R.B. GESKUS; P.W. K 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

ACC/AHA/ESC 2006 Guidelines for the Mana

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society

✍ Valentin Fuster; Lars E. Rydén; David S. Cannom; Harry J. Crijns; Anne B. Curtis 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 917 KB